Evidence map›Paper›PMID 39026293›Full record

ArticleBMC cancer2024

Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial.

Paul Nankivell, Piers Gaunt, Claire Gaunt, Julia Sissons, Evaggelia Liaskou, Yolande Jefferson, Tessa Fulton-Lieuw, Saloni Mittal, Hisham Mehanna, PETNECK2 Research Team

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Paul NankivellInstitute of Head and Neck Studies and Education (InHANSE), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK. p.c.nankivell@bham.ac.uk.
Piers GauntCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham Edgbaston, Birmingham, B15 2TT, UK.
Claire GauntCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham Edgbaston, Birmingham, B15 2TT, UK.
Julia SissonsCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham Edgbaston, Birmingham, B15 2TT, UK.
Evaggelia LiaskouCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham Edgbaston, Birmingham, B15 2TT, UK.
Yolande JeffersonCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham Edgbaston, Birmingham, B15 2TT, UK.
Tessa Fulton-LieuwInstitute of Head and Neck Studies and Education (InHANSE), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Saloni MittalInstitute of Head and Neck Studies and Education (InHANSE), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Hisham MehannaInstitute of Head and Neck Studies and Education (InHANSE), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
PETNECK2 Research Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39026293
PMCPMC11264710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.